AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial
← catalyst calendarSponsored by BioCardia, Inc. (industry) · BCDA — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
With available funding it was necessary for Sponsor to prioritize other studies. No study participants were consented or enrolled and no study sites were activated.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-04 | actual | When the study began enrolling |
| Primary completion | 2026-01-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-04 | actual | The whole study's end, after follow-up |
| First posted | 2022-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ARDS, Human
Intervention
- Biological: intravenous delivery of allogeneic bone marrow-derived MSCs — also filed as allogeneic NK1R+MSC
Primary outcome
what the primary-completion date above is the date OFNumber of product related adverse events through the duration of the study.
measured 3 months
Permalink · BCDA's whole pipeline · Catalyst calendar · Every registered study · What changed